Latest Operating Cash Flow News

Corazon Mining finished the September quarter with A$7.285 million in cash after raising A$16.5 million through equity issuance and spending A$7.75 million on tenements. The company reported an estimated 4.04 quarters of funding at its current cash outflow rate.

Altamin has completed the technical work underpinning its Lazio Scoping Study, but pushed the release to the end of Q1 2027 while reporting A$1.56 million in cash and a 1.41-quarter funding estimate. The company has drawn A$1 million from a shareholder-linked facility and is relying on further debt, grant reimbursements, a possible Gorno transaction and potential equity funding to support its plans.

GR Engineering Services delivered stronger FY26 earnings and lifted its dividend, but the scale of its new project pipeline is bringing a substantial working-capital requirement. The ASX-listed contractor is forecasting FY27 revenue of A$825 million to A$850 million after securing more than A$1 billion in contracts since April.

DataDot Technology Limited (ASX:DDT) delivered a stronger FY26, with revenue rising 14.1% to $3.85 million and profit before tax nearly tripling to $327,420. The sharper result was driven largely by PropertyVAULT’s first full year of insurance services, although key insurer relationships remain pilots or works in progress.

Kaiser Reef produced 6,263 ounces of gold in the September quarter while lifting cash and bullion to A$40 million and fully repaying its Auramet gold loan after quarter end. Henty replaced mined reserves, while Maldon’s exploration program moved underground despite a negative operating cash contribution.

ReNerve has reported its strongest quarter yet, with sales climbing to $584,000 as the medical device company expands across Asia-Pacific. The growth came alongside a secured funding drawdown, leaving the company with $1.62 million in cash but continued negative operating cash flow.

FINEOS lifted its quarterly client receipts 47% and ended September with €51.7 million in cash, while maintaining FY26 revenue guidance of €147 million to €152 million. The stronger cash position was helped by the delayed collection of approximately €8 million in invoices, but no new sales were finalised during the quarter.

Mach7 Technologies has delivered its first positive first-quarter operating cash flow, while ARR rose 8.5% in constant currency to A$23.5 million. The next test is whether increased product investment and the Flamingo rollout can translate into contracted sales.

Adveritas lifted annualised recurring revenue 47% to $17.9 million while building new customer channels through its SME platform, US partner Vaudit and ChatGPT ad-fraud detection. The growth story is developing alongside a sharp cash-burn warning, with the company reporting 0.82 quarters of funding before its post-quarter-end placement.

EMVision Medical Devices has taken its pivotal emu™ trial beyond 230 participants while preparing to add acute ischaemic stroke detection to the FDA validation program. The ASX-listed medtech ended September with $18.1 million in cash and $3.7 million in remaining grant funding.

Mayne Pharma’s unaudited first-quarter revenue fell 2% to A$95.7 million, while underlying EBITDA dropped 52% as generic competition hit Dermatology. Strong prescription growth in Women’s Health and DistributeRx offered a partial counterweight, alongside progress on key legal disputes.

Pure Foods Tasmania reported a sharper September quarter, with customer receipts rising to A$1.22 million while operating cash outflow fell to A$311,000. The company remains cash flow negative and reliant on financing capacity, but says the figures mark progress towards a sustainable turnaround.